Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 8, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

IMWG consensus on risk stratification in multiple myeloma.

W J Chng¹, A Dispenzieri², C-S Chim³

¹1] Department of Haematology Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore [2] Experimental Therapeutics, Cancer Science Institute of Singapore, Singapore, Singapore [3] Department of Medicine, Yoo Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

|August 27, 2013

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Feasibility Trial Protocol for a Remote Intentional Music Listening Intervention to Support Mental Health in Individuals with Chronic Stroke.

medRxiv : the preprint server for health sciences·2025

Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024

Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023

Same author

Erratum to 'Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients': [ESMO Open Volume 7, Issue 1, February 2022, 100393].

ESMO open·2022

Same author

Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.

ESMO open·2022

Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021

This consensus statement proposes standardized risk categories for multiple myeloma patients. These categories will help stratify patients and guide personalized treatment strategies for better outcomes.

Area of Science:

Hematology
Oncology
Clinical Medicine

Background:

Multiple myeloma exhibits significant clinical and biological heterogeneity, leading to varied treatment responses and outcomes.
The expanding therapeutic landscape necessitates mechanisms to address this heterogeneity and personalize treatment.
Validated prognostic markers are crucial for stratifying patients into distinct risk groups.

Purpose of the Study:

To propose well-defined and applicable risk categories for multiple myeloma.
To establish gold-standard prognostic factors for clinical trials.
To provide a framework for rationalizing therapeutic approaches.

Main Methods:

Consensus statement development by the International Myeloma Working Group.
Review of current validated prognostic markers.

Related Experiment Videos

Last Updated: May 8, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Proposal of standardized risk stratification categories.

Main Results:

Defined easily applicable risk categories for multiple myeloma.
Recommended prognostic factors as gold standards for clinical trials.
Established a framework for rationalizing therapy selection.

Conclusions:

Standardized risk categories are essential for managing multiple myeloma heterogeneity.
These categories will guide treatment decisions and improve patient outcomes.
The proposed framework supports the development of advanced prognostic systems.